Advanced search
Publication Cover
Expert Review of Vaccines Volume 12, 2013 - Issue 7
Submit an article Journal homepage
305
Views
26
CrossRef citations to date
0
Altmetric
Special Focus: Vaccine Adjuvants - Review

Adjuvants containing natural and synthetic Toll-like receptor 4 ligands

Gregory C Ireton Infectious Disease Research Institute, 1124 Columbia St., Ste 400, Seattle, WA 98104, USA. [email protected]
&
Steven G Reed Infectious Disease Research Institute, 1124 Columbia St., Ste 400, Seattle, WA 98104, USA
Pages 793-807 | Published online: 09 Jan 2014

References

  • Wack A, Rappuoli R. Vaccinology at the beginning of the 21st century. Curr. Opin. Immunol. 17(4), 411–418 (2005).
  • Alving CR, Peachman KK, Rao M, Reed SG. Adjuvants for human vaccines. Curr. Opin. Immunol. 24(3), 310–315 (2012).
  • Bertholet S, Ireton GC, Ordway DJ et al. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci. Transl. Med. 2(53), 53ra74 (2010).
  • Coler RN, Baldwin SL, Shaverdian N et al. A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS ONE 5(10), e13677 (2010).
  • Johnson AG, Gains S, Landy M. Studies on the O antigen of Salmonella ryphosa V. Enhancement of antibody response to protein antigens by purified lipopolysaccharide. J. Exp. Med. 103(2), 225–246 (1956).
  • Kotani S, Takada H, Takahashi I et al. Immunobiological activities of synthetic lipid A analogs with low endotoxicity. Infect. Immun. 54(3), 673–682 (1986).
  • Kotani S, Takada H, Tsujimoto M et al. Synthetic lipid A with endotoxic and related biological activities comparable to those of a natural lipid A from an Escherichia coli re-mutant. Infect. Immun. 49(1), 225–237 (1985).
  • Needham BD, Carroll SM, Giles DK, Georgiou G, Whiteley M, Trent MS. Modulating the innate immune response by combinatorial engineering of endotoxin. Proc. Natl Acad. Sci. USA 110(4), 1464–1469 (2013).
  • Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 20, 197–216 (2002).
  • Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 449(7164), 819–826 (2007).
  • Kumar H, Kawai T, Akira S. Pathogen recognition in the innate immune response. Biochem. J. 420(1), 1–16 (2009).
  • Song DH, Lee JO. Sensing of microbial molecular patterns by Toll-like receptors. Immunol. Rev. 250(1), 216–229 (2012).
  • Beutler BA. TLRs and innate immunity. Blood 113(7), 1399–1407 (2009).
  • Pasare C, Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Microbes Infect. 6(15), 1382–1387 (2004).
  • Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388(6640), 394–397 (1997).
  • Poltorak A, He X, Smirnova I et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282(5396), 2085–2088 (1998).
  • Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 86(6), 973–983 (1996).
  • Matsushima N, Tanaka T, Enkhbayar P et al. Comparative sequence analysis of leucine-rich repeats (LRRs) within vertebrate Toll-like receptors. BMC Genomics 8, 124 (2007).
  • Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int. Immunol. 21(4), 317–337 (2009).
  • Kagan JC, Su T, Horng T, Chow A, Akira S, Medzhitov R. TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-β. Nat. Immunol. 9(4), 361–368 (2008).
  • Jin MS, Kim SE, Heo JY et al. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 130(6), 1071–1082 (2007).
  • Liu L, Botos I, Wang Y et al. Structural basis of Toll-like receptor 3 signaling with double-stranded RNA. Science 320(5874), 379–381 (2008).
  • Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 458(7242), 1191–1195 (2009).
  • Dasari P, Nicholson IC, Hodge G, Dandie GW, Zola H. Expression of Toll-like receptors on B lymphocytes. Cell. Immunol. 236(1–2), 140–145 (2005).
  • Gribar SC, Richardson WM, Sodhi CP, Hackam DJ. No longer an innocent bystander: epithelial Toll-like receptor signaling in the development of mucosal inflammation. Mol. Med. 14(9–10), 645–659 (2008).
  • Bulut Y, Michelsen KS, Hayrapetian L et al. Mycobacterium tuberculosis heat shock proteins use diverse Toll-like receptor pathways to activate pro-inflammatory signals. J. Biol. Chem. 280(22), 20961–20967 (2005).
  • O’Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat. Rev. Immunol. 7(5), 353–364 (2007).
  • O’Neill LA, Bryant CE, Doyle SL. Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol. Rev. 61(2), 177–197 (2009).
  • Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 124(4), 783–801 (2006).
  • Akira S, Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 4(7), 499–511 (2004).
  • Barton GM, Kagan JC. A cell biological view of Toll-like receptor function: regulation through compartmentalization. Nat. Rev. Immunol. 9(8), 535–542 (2009).
  • Steinman RM, Pope M. Exploiting dendritic cells to improve vaccine efficacy. J. Clin. Invest. 109(12), 1519–1526 (2002).
  • Coler RN, Bertholet S, Moutaftsi M et al. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS ONE 6(1), e16333 (2011).
  • Krummen M, Balkow S, Shen L et al. Release of IL-12 by dendritic cells activated by TLR ligation is dependent on MyD88 signaling, whereas TRIF signaling is indispensable for TLR synergy. J. Leukoc. Biol. 88(1), 189–199 (2010).
  • Shen H, Tesar BM, Walker WE, Goldstein DR. Dual signaling of MyD88 and TRIF is critical for maximal TLR4-induced dendritic cell maturation. J. Immunol. 181(3), 1849–1858 (2008).
  • Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6(8), 769–776 (2005).
  • Raetz CR, Whitfield C. Lipopolysaccharide endotoxins. Annu. Rev. Biochem. 71, 635–700 (2002).
  • Galanos C, Lüderitz O, Rietschel ET et al. Synthetic and natural Escherichia coli free lipid A express identical endotoxic activities. Eur. J. Biochem. 148(1), 1–5 (1985).
  • Miyake K. Roles for accessory molecules in microbial recognition by Toll-like receptors. J. Endotoxin Res. 12(4), 195–204 (2006).
  • Nagai Y, Akashi S, Nagafuku M et al. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat. Immunol. 3(7), 667–672 (2002).
  • Kobayashi M, Saitoh S, Tanimura N et al. Regulatory roles for MD-2 and TLR4 in ligand-induced receptor clustering. J. Immunol. 176(10), 6211–6218 (2006).
  • Rietschel ET, Kirikae T, Schade FU et al. Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB J. 8(2), 217–225 (1994).
  • Kumazawa Y, Matsuura M, Homma JY, Nakatsuru Y, Kiso M, Hasegawa A. B cell activation and adjuvant activities of chemically synthesized analogues of the nonreducing sugar moiety of lipid A. Eur. J. Immunol. 15(2), 199–201 (1985).
  • Raetz CR. Biochemistry of endotoxins. Annu. Rev. Biochem. 59, 129–170 (1990).
  • Alexander C, Rietschel ET. Bacterial lipopolysaccharides and innate immunity. J. Endotoxin Res. 7(3), 167–202 (2001).
  • Hajjar AM, Ernst RK, Tsai JH, Wilson CB, Miller SI. Human Toll-like receptor 4 recognizes host-specific LPS modifications. Nat. Immunol. 3(4), 354–359 (2002).
  • Kusumoto S, Fukase K, Fukase Y et al. Structural basis for endotoxic and antagonistic activities: investigation with novel synthetic lipid A analogs. J. Endotoxin Res. 9(6), 361–366 (2003).
  • Hajjar AM, Ernst RK, Fortuno ES 3rd et al. Humanized TLR4/MD-2 mice reveal LPS recognition differentially impacts susceptibility to Yersinia pestis and Salmonella enterica. PLoS Pathog. 8(10), e1002963 (2012).
  • Johnson DA, Keegan DS, Sowell CG et al. 3-O-Desacyl monophosphoryl lipid A derivatives: synthesis and immunostimulant activities. J. Med. Chem. 42(22), 4640–4649 (1999).
  • Stöver AG, Da Silva Correia J, Evans JT et al. Structure-activity relationship of synthetic Toll-like receptor 4 agonists. J. Biol. Chem. 279(6), 4440–4449 (2004).
  • Cekic C, Casella CR, Eaves CA, Matsuzawa A, Ichijo H, Mitchell TC. Selective activation of the p38 MAPK pathway by synthetic monophosphoryl lipid A. J. Biol. Chem. 284(46), 31982–31991 (2009).
  • Seydel U, Schromm AB, Brade L et al. Physicochemical characterization of carboxymethyl lipid A derivatives in relation to biological activity. FEBS J. 272(2), 327–340 (2005).
  • Ulmer AJ, Heine H, Feist W et al. Biological activity of synthetic phosphonooxyethyl analogs of lipid A and lipid A partial structures. Infect. Immun. 60(8), 3309–3314 (1992).
  • Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316(5831), 1628–1632 (2007).
  • Bowen WS, Minns LA, Johnson DA, Mitchell TC, Hutton MM, Evans JT. Selective TRIF-dependent signaling by a synthetic Toll-like receptor 4 agonist. Sci. Signal. 5(211), ra13 (2012).
  • Cekic C, Casella CR, Sag D et al. MyD88-dependent SHIP1 regulates proinflammatory signaling pathways in dendritic cells after monophosphoryl lipid A stimulation of TLR4. J. Immunol. 186(7), 3858–3865 (2011).
  • Kim HM, Park BS, Kim JI et al. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 130(5), 906–917 (2007).
  • Ohto U, Fukase K, Miyake K, Satow Y. Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa. Science 316(5831), 1632–1634 (2007).
  • Choe J, Kelker MS, Wilson IA. Crystal structure of human Toll-like receptor 3 (TLR3) ectodomain. Science 309(5734), 581–585 (2005).
  • Kang JY, Nan X, Jin MS et al. Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity 31(6), 873–884 (2009).
  • Ohto U, Fukase K, Miyake K, Shimizu T. Structural basis of species-specific endotoxin sensing by innate immune receptor TLR4/MD-2. Proc. Natl Acad. Sci. USA 109(19), 7421–7426 (2012).
  • Ribi E, Parker R, Strain S et al. Peptides as requirement for immunotherapy of the guinea-pig line 10 tumor with endotoxins. Cancer Immunol. Immunother. 12, 91–96 (1979).
  • Myers K, Truchot A, Ward J, Hudson Y, Ulrich J. A critical determinant of lipid A endotoxic activity. In: Cellular and Molecular Aspects of Endotoxin Reactions. Nowotny A, Spitzler J, Ziegler E (Eds). Elsevier, Amsterdam, The Netherlands, 145–156 (1990).
  • Ulrich J, Myers K. Monophosphoryl lipid A as an adjuvant. In: Vaccine Design: The Subunit and Adjuvant Approach. Powell M, Newman M (Eds). Plenum Press, New York, NY, USA, 495–524 (1995).
  • Casella CR, Mitchell TC. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell. Mol. Life Sci. 65(20), 3231–3240 (2008).
  • Elliott GT, McLeod RA, Perez J, Von Eschen KB. Interim results of a Phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma. Semin. Surg. Oncol. 9(3), 264–272 (1993).
  • Mitchell MS, Harel W, Kempf RA et al. Active-specific immunotherapy for melanoma. J. Clin. Oncol. 8(5), 856–869 (1990).
  • Evans JT, Cluff CW, Johnson DA, Lacy MJ, Persing DH, Baldridge JR. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev. Vaccines 2(2), 219–229 (2003).
  • Wheeler CM, Castellsagué X, Garland SM et al.; HPV PATRICIA Study Group. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 13(1), 100–110 (2012).
  • Didierlaurent AM, Morel S, Lockman L et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J. Immunol. 183(10), 6186–6197 (2009).
  • Abdulla S, Salim N, Machera F et al. Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02(D) malaria vaccine in infants living in a malaria-endemic region. Malar. J. 12, 11 (2013).
  • Agnandji ST, Lell B, Fernandes JF et al. A Phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N. Engl. J. Med. 367(24), 2284–2295 (2012).
  • Johnson AG. Molecular adjuvants and immunomodulators: new approaches to immunization. Clin. Microbiol. Rev. 7(3), 277–289 (1994).
  • Galanos C, Lüderitz O, Freudenberg M et al. Biological activity of synthetic heptaacyl lipid A representing a component of Salmonella minnesota R595 lipid A. Eur. J. Biochem. 160(1), 55–59 (1986).
  • Jiang ZH, Budzynski WA, Qiu D, Yalamati D, Koganty RR. Monophosphoryl lipid A analogues with varying 3-O-substitution: synthesis and potent adjuvant activity. Carbohydr. Res. 342(6), 784–796 (2007).
  • Jiang ZH, Bach MV, Budzynski WA, Krantz MJ, Koganty RR, Longenecker BM. Lipid A structures containing novel lipid moieties: synthesis and adjuvant properties. Bioorg. Med. Chem. Lett. 12(16), 2193–2196 (2002).
  • Martin OR, Zhou W, Wu X et al. Synthesis and immunobiological activity of an original series of acyclic lipid a mimics based on a pseudodipeptide backbone. J. Med. Chem. 49(20), 6000–6014 (2006).
  • Ishizaka ST, Hawkins LD. E6020: a synthetic Toll-like receptor 4 agonist as a vaccine adjuvant. Expert Rev. Vaccines 6(5), 773–784 (2007).
  • Morefield GL, Hawkins LD, Ishizaka ST, Kissner TL, Ulrich RG. Synthetic Toll-like receptor 4 agonist enhances vaccine efficacy in an experimental model of toxic shock syndrome. Clin. Vaccine Immunol. 14(11), 1499–1504 (2007).
  • Baldwin SL, Bertholet S, Reese VA, Ching LK, Reed SG, Coler RN. The importance of adjuvant formulation in the development of a tuberculosis vaccine. J. Immunol. 188(5), 2189–2197 (2012).
  • Wiley SR, Raman VS, Desbien A et al. Targeting TLRs expands the antibody repertoire in response to a malaria vaccine. Sci. Transl. Med. 3(93), 93ra69 (2011).
  • Mueller M, Lindner B, Kusumoto S, Fukase K, Schromm AB, Seydel U. Aggregates are the biologically active units of endotoxin. J. Biol. Chem. 279(25), 26307–26313 (2004).
  • Anderson RC, Fox CB, Dutill TS et al. Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Colloids Surf. B. Biointerfaces 75(1), 123–132 (2010).
  • Baldridge JR, Crane RT. Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines. Methods 19(1), 103–107 (1999).
  • Childers NK, Miller KL, Tong G et al. Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen. Infect. Immun. 68(10), 5509–5516 (2000).
  • Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol. 30(1), 23–32 (2009).
  • Hui GS, Hashimoto CN. Adjuvant formulations possess differing efficacy in the potentiation of antibody and cell mediated responses to a human malaria vaccine under selective immune genes knockout environment. Int. Immunopharmacol. 8(7), 1012–1022 (2008).
  • Clements CJ, Griffiths E. The global impact of vaccines containing aluminium adjuvants. Vaccine 20(Suppl. 3), S24–S33 (2002).
  • Hem SL, Hogenesch H. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev. Vaccines 6(5), 685–698 (2007).
  • Alving CR, Matyas GR. Design and selection of vaccine adjuvants: principles and practice. In: The Grand Challenge for the Future: Vaccines for Poverty-Related Diseases from Bench to Field. Kaufmann SHE, Lambert PH (Eds). Birkhauser Verlag, Basel, Switzerland, 99–118 (2005).
  • Zhu D, Huang S, Gebregeorgis E et al. Development of a direct alhydrogel formulation immunoassay (DAFIA). J. Immunol. Methods 344(1), 73–78 (2009).
  • Alving CR, Rao M. Lipid A and liposomes containing lipid A as antigens and adjuvants. Vaccine 26(24), 3036–3045 (2008).
  • Tollemar J, Klingspor L, Ringdén O. Liposomal amphotericin B (AmBisome) for fungal infections in immunocompromised adults and children. Clin. Microbiol. Infect. 7(Suppl. 2), 68–79 (2001).
  • Matyas GR, Wassef NM, Rao M, Alving CR. Induction and detection of antibodies to squalene. J. Immunol. Methods 245(1–2), 1–14 (2000).
  • Fries LF, Gordon DM, Richards RL et al. Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc. Natl Acad. Sci. USA 89(1), 358–362 (1992).
  • Richards RL, Rao M, Wassef NM, Glenn GM, Rothwell SW, Alving CR. Liposomes containing lipid A serve as an adjuvant for induction of antibody and cytotoxic T-cell responses against RTS,S malaria antigen. Infect. Immun. 66(6), 2859–2865 (1998).
  • Watson DS, Endsley AN, Huang L. Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. Vaccine 30(13), 2256–2272 (2012).
  • Fox CB, Friede M, Reed SG, Ireton GC. Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants. Subcell. Biochem. 53, 303–321 (2010).
  • Baudner BC, Ronconi V, Casini D et al. MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020). Pharm. Res. 26(6), 1477–1485 (2009).
  • Pichyangkul S, Gettayacamin M, Miller RS et al. Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum. Vaccine 22(29–30), 3831–3840 (2004).
  • Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 33(4), 492–503 (2010).
  • Baldwin SL, Shaverdian N, Goto Y et al. Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 27(43), 5956–5963 (2009).
  • Windish HP, Duthie MS, Misquith A et al. Protection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidate. Vaccine 29(44), 7842–7848 (2011).
  • Bertholet S, Goto Y, Carter L et al. Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine 27(50), 7036–7045 (2009).
  • Coler RN, Goto Y, Bogatzki L, Raman V, Reed SG. Leish-111f, a recombinant polyprotein vaccine that protects against visceral leishmaniasis by elicitation of CD4+ T cells. Infect. Immun. 75(9), 4648–4654 (2007).
  • Coler RN, Skeiky YA, Bernards K et al. Immunization with a polyprotein vaccine consisting of the T-cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect. Immun. 70(8), 4215–4225 (2002).
  • Skeiky YA, Alderson MR, Ovendale PJ et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J. Immunol. 172(12), 7618–7628 (2004).
  • Reed S, Lobet Y. Tuberculosis vaccine development; from mouse to man. Microbes Infect. 7(5–6), 922–931 (2005).
  • Reed SG, Coler RN, Dalemans W et al. Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in Cynomolgus monkeys. Proc. Natl Acad. Sci. USA 106(7), 2301–2306 (2009).
  • Skeiky YA, Alderson MR, Ovendale PJ et al. Protection of mice and guinea pigs against tuberculosis induced by immunization with a single Mycobacterium tuberculosis recombinant antigen, MTB41. Vaccine 23(30), 3937–3945 (2005).
  • Vélez ID, Gilchrist K, Martínez S et al. Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis. Vaccine 28(2), 329–337 (2009).
  • Carpenter S, O’Neill LA. Recent insights into the structure of Toll-like receptors and post-translational modifications of their associated signalling proteins. Biochem. J. 422(1), 1–10 (2009).

Patent

  • Crane RT. Aqueous immunologic adjuvant compositions of monophosphoryl lipid A. US Patent 6,491,919 B2 (2002).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.